Korean CDMO giant’s takeover of Rockville facility comes after US Congress passes Biosecure Act
Samsung Biologics said Monday it has inked a $280 million agreement to acquire GSK’s biopharmaceutical manufacturing plant in Rockville, Maryland, securing the Korean contract development and manufacturing organization leader its first production site in the United States.
According to Samsung Biologics, its wholly owned US subsidiary Samsung Biologics America will acquire 100 percent of Human Genome Sciences.
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.